METHOD FOR PRODUCING ALPHA-SANTALENE
Technical field
The present invention provides a method of producing a-santalene, said method
comprising contacting at least one polypeptide with famesyl phyrophosphate (FPP). In
particular, said method may be carried out in vitro or in vivo to produce a-santalene, a
very useful compound in the fields of perfumery and flavoring. The present invention also
provides the amino acid sequence of a polypeptide useful in the method of the invention. A
nucleic acid encoding the polypeptide of the invention and an expression vector containing
said nucleic acid are also part of the present invention. A non-human host organism or a
cell transformed to be used in the method of producing a-santalene is also an object of the
present invention.
Prior art
Terpenes are found in most organisms (microorganisms, animals and plants). These
compounds are made up of five carbon units called isoprene units and are classified by the
number of these units present in their structure. Thus monoterpenes, sesquiterpenes and
diterpenes are terpenes containing 10, 15 and 20 carbon atoms respectively.
Sesquiterpenes, for example, are widely found in the plant kingdom. Many sesquiterpene
molecules are known for their flavor and fragrance properties and their cosmetic, medicinal
and antimicrobial effects. Over 300 sesquiterpene hydrocarbons and 3000 sesquiterpenoids
have been identified and many new structures are identified each year. Plant extracts
obtained by different means such as steam distillation or solvent extraction are used as
source of terpenes. Terpene molecules are often used as such, but in some cases chemical
reactions are used to transform the terpenes into other high value molecules.
Biosynthetic production of terpenes involves enzymes called terpene synthases.
There is virtually an infinity of sesquiterpene synthases present in the plant kingdom, all
using the same substrate (famesyl pyrophosphate, FPP) but having different product
profiles. Genes and cDNAs encoding sesquiterpene synthases have been cloned and the
corresponding recombinant enzymes characterized. The biosynthesis of terpenes in plants
and other organisms has been extensively studied and is not further detailed in here, but
reference is made to Dewick, Nat. Prod. Rep., 2002, 19, 181-222, which reviews the state

of the art of terpene biosynthetic pathways.
a-santalene is a naturally occurring sesquiterpene molecule. The (+)- isomer can be
used as starting material for the chemical synthesis or the biosynthesis of (Z)-(+)-α-
santalol, which is an important constituent of sandalwood oil. Sandalwood oil is an
important perfumery ingredient obtained by distillation of the heartwood of Santalum
species. Sandalwood is also largely used for incenses and traditional medicine. The oil
contains 90% of sesquiterpene alcohols. (Z)-(+)-α-santalol and (Z)-(-)-β-santalol represent
the major constituents (respectively 45-47% and 20-30%) and are mainly responsible for
the typical sweet-woody and balsamic odour of sandalwood oil. Other constituents such as
epi-P-santalol and trans-a-bergamotol are also present and may contribute to the
sandalwood note.
Generally, the price and availability of plant natural extracts are dependent on the
abundance, oil yield and geographical origin of the plants. In addition, the availability and
quality of natural extracts is very much dependent on climate and other local conditions
leading to variability from year to year, rendering the use of such ingredients in high
quality perfumery very difficult or even impossible some years. Due to over-exploitation of
the natural resources, difficulties of cultivation, slow growth of the Santalum plants, the
availabilities of sandalwood raw material has dramatically decreased during the past
decades. Therefore, it would be an advantage to provide a source of (Z)-(+)-α-santalol,
which is less subjected to fluctuations in availability and quality. A chemical synthesis of
the sandalwood sesquiterpene constituents is so far not available. A biochemical pathway
leading to the synthesis of (+)-a-santalene, which could then be used to produce (Z)-(+)-α-
santalol, would therefore be of great interest. Given the difficulty to control sesquiterpene
production in Santalum species, alternate plant sources were sought.
Santalane type sesquiterpene, and particurly sesquiterpenes with the a-santalane
skeleton, were identified in several plant species. Clausena lansium, a plant from the
Rutaceae family has been reported to contain large quantities of santalane sesquiterpenes
in the leaves. Zhao and coworkers (Zhao et al, Z. Naturforsch, 2004, 59c, 153-156) have
analyzed the leaves of C. lansium from China and detected the presence of a-santalol and
β-santalol. The analysis of the leaves of C. lansium from Cuba, has revealed the presence
of (Z)-α-santalol, epi-β-santalol, (Z)-β-santalol and (E)-β-santalol (Pino et al., J. Essent.
Oil Res., 2006, 18, 139-141). Surprisingly the analysis of different parts of C. lansium

from Thailand origin did not show the presence of sesquiterpenes with santalane skeletons
(Chokeprasert et al, Journal of Food Composition and Analysis, 2007, 20(1), 52-56).
A sesquiterpene synthase capable of synthesizing at least one bi-cyclic and/or tri-
cyclic sesquiterpene having a santalane carbon skeleton, the corresponding nucleic acid
and a method for producing such compounds having a santalane carbon skeleton are
disclosed in the International patent application WO 2006/134523. (+)-epi-β-santalene, (-)-
β-santalene, (+)-β-santalene, (+)-a-santalene and (-)-α-santalene are cited as examples of
compounds having a santalane carbon skeleton. Nevertheless, the sesquiterpene synthase
provided in the examples does not produce a-santalene. Only epi-β-santalene is produced.
The properties of this compound are very different from those of a-santalene. In particular,
epi-β-santalene is of no interest in the synthesis of (Z)-(+)-α-santalol. Moreover, the
sesquiterpene synthase disclosed in WO 2006/134523 shares only 37% identity with the
sequence of the invention.
Terpene synthases having a certain percentage of sequence identity with the
sequence of the a-santalene synthase of the present invention have also been found in the
sequences databases. Nevertheless, the percentage of identity between the known
sesquiterpene synthases and the polypeptide of the invention is very low. The closest
protein sequence to the (+)-α-santalene synthase of the invention is a (E)-β-farnesene
synthase from Citrus junos (NCBI access No. AAK54279; Maruyama et al, Biol. Pharm.
Bull., 2001, 24(10), 1171-1175) which shares 67 to 68% amino acid sequence identity
with the a-santalene synthase of the invention.
In addition to the difference between the sequences themselves, it also has to be
pointed out that the structure and the properties of the products synthesized by the above-
mentioned enzyme are very different from those of a-santalene. In particular (E)-β-
farnesene is not suitable as a starting material for the synthesis of (Z)-(+)-α-santaloL which
is a very useful ingredient in the field of perfumery.
An a-santalene synthase is disclosed in WO 2008/142318. This document was not
published at the priority date of the present application. It describes an enzyme capable of
catalyzing the transformation of Z,Z-famesyl pyrophosphate to a-santalene. Therefore the
reaction catalyzed by the prior art enzyme is different from the one catalyzed by the
synthase of the present invention, which starts from E,E-farnesyl pyrophosphate.
Moreover, the a-santalene synthase of the invention shares only 23.8% of sequence

identity with the one described in WO 2008/142318.
Despite extensive studies of terpene cyclization, the isolation and characterization
of the terpene synthases is still difficult, particularly in plants, due to their low abundance,
their often transient expression patterns, and the complexity of purifying them from the
mixtures of resins and phenolic compounds in tissues where they are expressed.
It is an objective of the present invention to provide methods for making (+)-α-
santalene in an economic way, as indicated above. Accordingly, the present invention has
the objective to produce (+)-α-santalene while having little waste, a more energy and
resource efficient process and while reducing dependency on fossil fuels. It is a further
objective to provide enzymes capable of synthesizing a-santalene, which is useful as
perfumery and/or aroma ingredients.
Abbreviations Used
bp base pair
kb kilo base
BSA bovine serum albumin
DMAPP dimethylallyl diphosphate
DNA deoxyribonucleic acid
cDNA complementary DNA
dT deoxy thymine
dNTP deoxy nucleotide triphosphate
DTT dithiothreitol
FPP famesyl pyrophosphate
GC gaseous chromatograph
idi isopentenyl diphosphate isomerase
IPP isopentenyl diphosphate
IPTG isopropyl-D-thiogalacto-pyranoside
LB lysogeny broth
MOPSO 3-(N-morpholino)-2-hydroxypropanesulfonic acid
MS mass spectrometer
mvaK1 mevalonate kinase
mvaK2 mevalonate diphosphate kinase

NMR nuclear magnetic resonance
PCR polymerase chain reaction
RMCE recombinase-mediated cassette exchange
3' -/5 '-RACE 3' and 5' rapid amplification of cDNA ends
RNA ribonucleic acid
mRNA messenger ribonucleic acid
Description of the invention
The present invention provides a method to biosynthetically produce α-santalene in
an economic, reliable and reproducible way.
A "sesquiterpene synthase" or a "polypeptide having a sesquiterpene synthase
activity", is intended here as a polypeptide capable of catalyzing the synthesis of a
sesquiterpene molecule or of a mixture of sesquiterpene molecules from the acyclic terpene
precursor FPP.
As an "a-santalene synthase" or as a "polypeptide having an a-santalene synthase
activity", we mean here a polypeptide capable of catalyzing the synthesis of a-santalene, in
the form of any of its stereoisomers or a mixture thereof, starting from FPP. a-Santalene
may be the only product or may be part of a mixture of sesquiterpenes.
As a "(+)-α-santalene synthase" or as a "polypeptide having a (+)-α-santalene
synthase activity", we mean here a polypeptide capable of catalyzing the synthesis of (+)-
α-santalene starting from FPP. (+)-α-santalene may be the only product or may be part of a
mixture of sesquiterpenes. The (+)-α-santalene synthase is a particular example of a-
santalene synthase.
The ability of a polypeptide to catalyze the synthesis of a particular sesquiterpene
(for example (+)-α-santalene) can be simply confirmed by performing the enzyme assay as
detailed in Example 4.
According to a preferred embodiment of the invention, FPP is in the form of
(2E,6E)-FPP.
According to the present invention, polypeptides are also meant to include
truncated polypeptides provided that they keep their sesquiterpene synthase activity as
defined in any of the above embodiments and that they share at least the defined
percentage of identity with the corresponding fragment of SEQ ID NO: 1.

As intended herein below, "a nucleotide sequence obtained by modifying SEQ ID
NO:2" encompasses any sequence that has been obtained by changing the sequence of
SEQ ID NO:2 using any method known in the art, for example by introducing any type of
mutations such as deletion, insertion or substitution mutations. Examples of such methods
are cited in the part of the description relative to the variant polypeptides and the methods
to prepare them.
The percentage of identity between two peptidic or nucleotidic sequences is a
function of the number of amino acids or nucleotide residues that are identical in the two
sequences when an alignment of these two sequences has been generated. Identical
residues are defined as residues that are the same in the two sequences in a given position
of the alignment. The percentage of sequence identity, as used herein, is calculated from
the optimal alignment by taking the number of residues identical between two sequences
dividing it by the total number of residues in the shortest sequence and multiplying by 100.
The optimal alignment is the alignment in which the percentage of identity is the highest
possible. Gaps may be introduced into one or both sequences in one or more positions of
the alignment to obtain the optimal alignment. These gaps are then taken into account as
non-identical residues for the calculation of the percentage of sequence identity.
Alignment for the purpose of determining the percentage of amino acid or nucleic
acid sequence identity can be achieved in various ways using computer programs and for
instance publicly available computer programs available on the world wide web.
Preferably, the BLAST program (Tatiana et al, FEMS Microbiol Lett., 1999, 174:247-
250, 1999) set to the default parameters, available from the National Center for
Biotechnology Information (NCBI) at
http://www.ncbi.nlm.nih.gov/BLAST/b12seq/wblast2.cgi, can be used to obtain an optimal
alignment of peptidic or nucleotidic sequences and to calculate the percentage of sequence
identity.
One object of the present invention is therefore a method for producing α-santalene
comprising
a) contacting FPP with at least one polypeptide having an α-santalene synthase activity
and comprising an amino acid sequence at least 50% identical to SEQ ID NO:1;
b) optionally, isolating the α-santalene produced in step a).

According to a preferred embodiment, the method is a method for producing
α-santalene as a major product. According to an even more preferred embodiment,
α-santalene represents at least 60%, preferably at least 80%, preferably at least 90%,
preferably at least 92% of the product produced by the method of the invention.
According to a more preferred embodiment, the method is a method for producing
(+)-α-santalene and the polypeptide having an α-santalene synthase activity has a (+)-α-
santalene synthase activity.
According to an even more preferred embodiment, the method is a method for
producing (+)-α-santalene as a major product. According to a most preferred embodiment,
(+)-α-santalene represents at least 60%, preferably at least 80%, preferably at least 90%,
preferably at least 92% of the products produced by the method of the invention.
The method can be carried out in vitro as well as in vivo, as will be explained in
details further on.
The polypeptide to be contacted with FPP in vitro can be obtained by extraction
from any organism expressing it, using standard protein or enzyme extraction technologies.
If the host organism is a unicellular organism or cell releasing the polypeptide of the
invention into the culture medium, the polypeptide may simply be collected from the
culture medium, for example by centrifugation, optionally followed by washing steps and
re-suspension in suitable buffer solutions. If the organism or cell accumulates the
polypeptide within its cells, the polypeptide may be obtained by disruption or lysis of the
cells and further extraction of the polypeptide from the cell lysate.
The polypeptide having an α-santalene synthase activity, either in an isolated form
or together with other proteins, for example in a crude protein extract obtained from
cultured cells or microorganisms, may then be suspended in a buffer solution at optimal
pH. If adequate, salts, BSA and other kinds of enzymatic co-factors, may be added in
order to optimize enzyme activity. Appropriate conditions are described in more details in
the Examples further on.
The precursor FPP may then be added to the suspension or solution, which is then
incubated at optimal temperature, for example between 15 and 40°C, preferably between
25 and 35°C, more preferably at 30°C. After incubation, the α-santalene produced may be
isolated from the incubated solution by standard isolation procedures, such as solvent
extraction and distillation, optionally after removal of polypeptides from the solution.

According to another preferred embodiment, the method of any of the above-
described embodiments is carried out in vivo. In this case, step a) comprises cultivating a
non-human host organism or cell capable of producing FPP and transformed to express at
least one polypeptide comprising an amino acid sequence at least 50% identical to SEQ ID
NO:1 and having an α-santalene synthase activity, under conditions conducive to the
production of α-santalene.
According to a more preferred embodiment, the method further comprises, prior to
step a), transforming a non human organism or cell capable of producing FPP with at least
one nucleic acid encoding a polypeptide comprising an amino acid sequence at least 50%
identical to SEQ ID NO:l and having an α-santalene synthase activity, so that said
organism expresses said polypeptide.
These embodiments of the invention are particularly advantageous since it is
possible to carry out the method in vivo without previously isolating the polypeptide. The
reaction occurs directly within the organism or cell transformed to express said
polypeptide.
According to a particular embodiment of the invention, the at least one nucleic acid
encoding the α-santalene synthase comprises a nucleotide sequence at least 50%,
preferably at least 55%, preferably at least 60%, preferably at least 65%, preferably at least
70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably
at least 90%, more preferably at least 95% and even more preferably at least 98% identical
to SEQ ID NO:2 or the complement thereof. According to a more preferred embodiment,
said nucleic acid comprises the nucleotide sequence SEQ ID NO:2 or the complement
thereof. In an even more preferred embodiment, said nucleic acid consists of SEQ ID
NO:2 or the complement thereof.
According to a more preferred embodiment the at least one nucleic acid used in any
of the above embodiments comprises a nucleotide sequence that has been obtained by
modifying SEQ ID NO:2. According to an even more preferred embodiment, said at least
one nucleic acid consists of a nucleotide sequence that has been obtained by modifying
SEQ ID NO:2.
According to another embodiment, the at least one nucleic acid is isolated from
Clausena lansium.
The organism or cell is meant to "express" a polypeptide, provided that the

organism or cell is transformed to harbor a nucleic acid encoding said polypeptide, this
nucleic acid is transcribed to mRNA and the polypeptide is found in the host organism or
cell. The term "express" encompasses "heterologously express" and "over-express", the
latter referring to levels of mRNA, polypeptide and/or enzyme activity over and above
what is measured in a non-transformed organism or cell. A more detailed description of
suitable methods to transform a non-human host organism or cell will be described later on
in the part of the specification that is dedicated to such transformed non-human host
organisms or cells as specific objects of the present invention and in the examples.
A particular organism or cell is meant to be "capable of producing FPP" when it
produces FPP naturally or when it does not produce FPP naturally but is transformed to
produce FPP, either prior to the transformation with a nucleic acid as described herein or
together with said nucleic acid. Organisms or cells transformed to produce a higher
amount of FPP than the naturally occurring organism or cell are also encompassed by the
"organisms or cells capable of producing FPP". Methods to transform organisms, for
example microorganisms, so that they produce FPP are already known in the art. Such
methods can for example be found in the literature, for example in the following
publications Martin, V.J., Pitera, D.J., Withers, ST., Newman, J.D., and Keasling, J.D.
Nat Biotechnol., 2003, 21(7), 796-802 (transformation of E. coli); Wu, S., Schalk, M.,
Clark, A., Miles, R.B., Coates, R., and Chappell, J., Nat Biotechnol., 2006, 24(11), 1441-
1447 (transformation of plants); Takahashi, S., Yeo, Y., Greenhagen, B. T., McMullin, T.,
Song, L., Maurina-Brunker, J., Rosson, R., Noel, J., Chappell, J, Biotechnology and
Bioengineering, 2007, 97(1), 170-181 (transformation of yeast). .
To carry out the invention in vivo, the host organism or cell is cultivated under
conditions conducive to the production of α-santalene. Accordingly, if the host is a
transgenic plant, optimal growth conditions are provided, such as optimal light, water and
nutrient conditions, for example. If the host is a unicellular organism, conditions conducive
to the production of α-santalene may comprise addition of suitable cofactors to the culture
medium of the host. In addition, a culture medium may be selected, so as to maximize a-
santalene synthesis. Optimal culture conditions are described in a more detailed manner in
the following Examples.
Non-human host organisms suitable to carry out the method of the invention in
vivo may be any non-human multicellular or unicellular organisms. In a preferred

embodiment, the non-human host organism used to carry out the invention in vivo is a
plant, a prokaryote or a fungus. Any plant, prokaryote or fungus can be used. Particularly
useful plants are those that naturally produce high amounts of terpenes. In a more
preferred embodiment, the plant is selected from the family of Solanaceae, Poaceae,
Brassicaceae, Fabaceae, Malvaceae, Asteraceae or Lamiaceae. For example, the plant is
selected from the genera Nicotiana, Solarium, Sorghum, Arabidopsis, Brassica (rape),
Medicago (alfalfa), Gossypium (cotton), Artemisia, Salvia and Mentha. Preferably, the
plant belongs to the species of Nicotiana tabacum.
In a more preferred embodiment the non-human host organism used to carry out
the method of the invention in vivo is a microorganism. Any microorganism can be used
but according to an even more preferred embodiment said microorganism is a bacteria or
yeast. Most preferably, said bacteria is E. coli and said yeast is Saccharomyces cerevisiae.
Some of these organisms do not produce FPP naturally. To be suitable to carry out
the method of the invention, these organisms have to be transformed to produce said
precursor. They can be so transformed either before the modification with the nucleic acid
described according to any of the above embodiments or simultaneously, as explained
above.
Isolated higher eukaryotic cells can also be used, instead of complete organisms, as
hosts to carry out the method of the invention in vivo. Suitable eukaryotic cells may be any
non-human cell, but are preferably plant or fungal cells.
According to a preferred embodiment, the at least one polypeptide having an a-
santalene synthase activity used in any of the above-described embodiments or encoded by
the nucleic acid used in any of the above-described embodiments comprises an amino acid
sequence at least 55%, preferably at least 60%, preferably at least 65%, preferably at least
70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably
at least 90%, more preferably at least 95% and even more preferably at least 98% identical
to SEQ ID NO:1. According to a more preferred embodiment, said polypeptide comprises
the amino acid sequence SEQ ID NO:1. In an even more preferred embodiment, said
polypeptide consists of SEQ ID NO: 1.
According to another preferred embodiment, the at least one polypeptide having an
α-santalene synthase activity used in any of the above-described embodiments or encoded
by the nucleic acid used in any of the above-described embodiments comprises an amino

acid sequence that is a variant of SEQ ID NO:1 obtained by genetic engineering. In other
terms, said polypeptide comprises an amino acid sequence encoded by a nucleotide
sequence that has been obtained by modifying SEQ ID NO:2. According to a more
preferred embodiment, the at least one polypeptide having an α-santalene synthase activity
used in any of the above-described embodiments or encoded by the nucleic acid used in
any of the above-described embodiments consists of an amino acid sequence that is a
variant of SEQ ID NO:1 obtained by genetic engineering, i.e. an amino acid sequence
encoded by a nucleotide sequence that has been obtained by modifying SEQ ID NO:2.
As used herein, the polypeptide is intended as a polypeptide or peptide fragment
that encompasses the amino acid sequences identified herein, as well as truncated or
variant polypeptides, provided that they keep their activity as defined above and that they
share at least the defined percentage of identity with the corresponding fragment of SEQ
IDNO:1.
Examples of variant polypeptides are naturally occurring proteins that result from
alternate mRNA splicing events or form proteolytic cleavage of the polypeptides described
herein. Variations attributable to proteolysis include, for example, differences in the N- or
C- termini upon expression in different types of host cells, due to proteolytic removal of
one or more terminal amino acids from the polypeptides of the invention. Polypeptides
encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of the
invention, as described thereafter, are also encompassed by the invention.
Polypeptide variants resulting from a fusion of additional peptide sequences at the
amino and carboxyl terminal ends can also be used in the methods of the invention. In
particular such a fusion can enhance expression of the polypeptides, be useful in the
purification of the protein or improve the enzymatic activity of the polypeptide in a desired
environment or expression system. Such additional peptide sequences may be signal
peptides, for example. Accordingly, the present invention encompasses methods using
variant polypeptides, such as those obtained by fusion with other oligo- or polypeptides
and/or those which are linked to signal peptides. Polypeptides resulting from a fusion with
another functional protein, such as another protein from the terpene biosynthesis pathway,
can also be advantageously be used in the methods of the invention.
According to another embodiment, the at least one polypeptide having an
α-santalene synthase activity used in any of the above-described embodiments or encoded

by the nucleic acid used in any of the above-described embodiments is isolated from
Clausena lansium.
An important tool to carry out the method of the invention is the polypeptide itself.
A polypeptide having an α-santalene synthase activity and comprising an amino acid
sequence at least 50% identical to SEQ ID NO:1 is therefore another object of the present
invention.
According to a preferred embodiment, the polypeptide is capable of producing a-
santalene as a major product. According to an even more preferred embodiment, it is
capable of producing a mixture of sesquiterpenes wherein α-santalene represents at least
60%, preferably at least 80%, preferably at least 90%, preferably at least 92% of the
sesquiterpenes produced.
According to a more preferred embodiment, the polypeptide has a (+)-α-santalene
synthase activity.
According to an even more preferred embodiment, the polypeptide is capable of
producing (+)-α-santalene as a major product. According to an even more preferred
embodiment, it is capable of producing a mixture of sesquiterpenes wherein (+)-α-
santalene represents at least 60%, preferably at least 80%, preferably at least 90%,
preferably at least 92% of the sesquiterpenes produced.
According to a preferred embodiment, the polypeptide comprises an amino acid
sequence at least 55%, preferably at least 60%, preferably at least 65%, preferably at least
70%, preferably at least 75%, preferably at least 80%, preferably at least 85%, preferably
at least 90%, more preferably at least 95% and even more preferably at least 98% identical
to SEQ ID NO:1. According to a more preferred embodiment, the polypeptide comprises
the amino acid sequence SEQ ID NO:1. According to an even more preferred
embodiment, the polypeptide consists of SEQ ID NO: 1.
According to another preferred embodiment, the at least one polypeptide comprises
an amino acid sequence that is a variant of SEQ ID NO:1 obtained by genetic engineering.
In other terms, said polypeptide comprises an amino acid sequence encoded by a
nucleotide sequence that has been obtained by modifying SEQ ID NO:2. According to a
more preferred embodiment, the at least one polypeptide having an α-santalene synthase
activity consists of an amino acid sequence that is a variant of SEQ ID NO:1 obtained by

genetic engineering, i.e. an amino acid sequence encoded by a nucleotide sequence that has
been obtained by modifying SEQ ID NO:2.
According to another embodiment, the polypeptide is isolated form Clausena
lansium.
As used herein, the polypeptide is intended as a polypeptide or peptide fragment
that encompasses the amino acid sequences identified herein, as well as truncated or
variant polypeptides, provided that they keep their activity as defined above and that they
share at least the defined percentage of identity with the corresponding fragment of SEQ
IDNO:1.
Examples of variant polypeptides are naturally occurring proteins that result from
alternate mRNA splicing events or form proteolytic cleavage of the polypeptides described
herein. Variations attributable to proteolysis include, for example, differences in the N- or
C- termini upon expression in different types of host cells, due to proteolytic removal of
one or more terminal amino acids from the polypeptides of the invention. Polypeptides
encoded by a nucleic acid obtained by natural or artificial mutation of a nucleic acid of the
invention, as described thereafter, are also encompassed by the invention.
Polypeptide variants resulting from a fusion of additional peptide sequences at the
amino and carboxyl terminal ends are also encompassed by the polypeptides of the
invention. In particular such a fusion can enhance expression of the polypeptides, be useful
in the purification of the protein or improve the enzymatic activity of the polypeptide in a
desired environment or expression system. Such additional peptide sequences may be
signal peptides, for example. Accordingly, the present invention encompasses variants of
the polypeptides of the invention, such as those obtained by fusion with other oligo- or
polypeptides and/or those which are linked to signal peptides. Polypeptides resulting from
a fusion with another functional protein, such as another protein from the terpene
biosynthesis pathway, are also encompassed by the polypeptides of the invention.
As mentioned above, the nucleic acid encoding the polypeptide of the invention is a
useful tool to modify non-human host organisms or cells intended to be used when the
method is carried out in vivo.
A nucleic acid encoding a polypeptide according to any of the above-described
embodiments is therefore also an object of the present invention.

According to a preferred embodiment, the nucleic acid comprises a nucleotide
sequence at least 50%, preferably at least 55%, preferably at least 60%, preferably at least
65%, preferably at least 70%, preferably at least 75%, preferably at least 80%, preferably
at least 85%, preferably at least 90%, more preferably at least 95% and even more
preferably at least 98% identical to SEQ ID NO:2 or the complement thereof. According
to a more preferred embodiment, the nucleic acid comprises the nucleotide sequence SEQ
ID NO:2 or the complement thereof. According to an even more preferred embodiment,
the nucleic acid consists of SEQ ID NO:2 or the complement thereof
According to another embodiment, the nucleic acid is isolated from Clausena
lansium.
The nucleic acid of the invention can be defined as including deoxyribonucleotide
or ribonucleotide polymers in either single- or double-stranded form (DNA and/or RNA).
The terms "nucleotide sequence" should also be understood as comprising a
polynucleotide molecule or an oligonucleotide molecule in the form of a separate fragment
or as a component of a larger nucleic acid. Nucleic acids of the invention also encompass
certain isolated nucleotide sequences including those that are substantially free from
contaminating endogenous material. The nucleic acid of the invention may be truncated,
provided that it encodes a polypeptide encompassed by the present invention, as described
above.
According to a more preferred embodiment, the at least one nucleic acid according
to any of the above embodiments comprises a nucleotide sequence that has been obtained
by modifying SEQ ID NO:2. Preferably said nucleic acid consists of a nucleotide sequence
that has been obtained by modifying SEQ ID NO:2.
The nucleic acids comprising a sequence obtained by mutation of SEQ ID NO:2 or
the complement thereof are encompassed by the invention, provided that the sequences
they comprise share at least the defined percentage of identity with the corresponding
fragments of SEQ ID NO:2 or with the complement thereof and provided that they encode
a polypeptide having an α-santalene synthase activity, as defined in any of the above
embodiments. Mutations may be any kind of mutations of these nucleic acids, such as point
mutations, deletion mutations, insertion mutations and/or frame shift mutations. A variant
nucleic acid may be prepared in order to adapt its nucleotide sequence to a specific
expression system. For example, bacterial expression systems are known to more

efficiently express polypeptides if amino acids are encoded by a preferred codon. Due to
the degeneracy of the genetic code, wherein more than one codon can encode the same
amino acid, multiple DNA sequences can code for the same polypeptide, all these DNA
sequences being encompassed by the invention.
Another important tool for transforming host organisms or cells suitable to carry
out the method of the invention in vivo is an expression vector comprising a nucleic acid
according to any embodiment of the invention. Such a vector is therefore also an object of
the present invention.
An "expression vector" as used herein includes any linear or circular recombinant
vector including but not limited to viral vectors, bacteriophages and plasmids. The skilled
person is capable of selecting a suitable vector according to the expression system. In one
embodiment, the expression vector includes the nucleic acid of the invention operably
linked to at least one regulatory sequence, which controls transcription, translation,
initiation and termination, such as a transcriptional promoter, operator or enhancer, or an
mRNA ribosomal binding site and, optionally, including at least one selection marker.
Nucleotide sequences are "operably linked" when the regulatory sequence functionally
relates to the nucleic acid of the invention.
The expression vectors of the present invention may be used in the methods for
preparing a genetically transformed host organism and/or cell, in host organisms and/or
cells harboring the nucleic acids of the invention and in the methods for producing or
making polypeptides having an α-santalene synthase activity, as disclosed further below.
Recombinant non-human host organisms and cells transformed to harbor at least
one nucleic acid of the invention so that it heterologously expresses or over-expresses at
least one polypeptide of the invention are also very useful tools to carry out the metiiod of
the invention. Such non-human host organisms and cells are therefore another object of the
present invention.
A nucleic acid according to any of the above-described embodiments can be used
to transform the non-human host organisms and cells and the expressed polypeptide can be
any of the above-described polypeptides.
Non-human host organisms of the invention may be any non-human multicellular or

unicellular organisms. In a preferred embodiment, the non-human host organism is a plant,
a prokaryote or a fungus. Any plant, prokaryote or fungus is suitable to be transformed
according to the present invention. Particularly useful plants are those that naturally
produce high amounts of terpenes. In a more preferred embodiment, the plant is selected
from the family of Solanaceae, Poaceae, Brassicaceae, Fabaceae, Malvaceae, Asteraceae
or Lamiaceae. For example, the plant is selected from the genera Nicotiana, Solarium,
Sorghum, Arabidopsis, Brassica (rape), Medicago (alfalfa), Gossypium (cotton),
Artemisia, Salvia and Mentha. Preferably, the plant belongs to the species of Nicotiana
tabacum.
In a more preferred embodiment the non-human host organism is a microorganism.
Any microorganism is suitable for the present invention, but according to an even more
preferred embodiment said microorganism is a bacteria or yeast. Most preferably, said
bacteria is E. coli and said yeast is Saccharomyces cerevisiae.
Isolated higher eukaryotic cells can also be transformed, instead of complete
organisms. As higher eukaryotic cells, we mean here any non-human eukaryotic cell except
yeast cells. Preferred higher eukaryotic cells are plant cells or fungal cells.
The term "transformed" refers to the fact that the host was subjected to genetic
engineering to comprise one, two or more copies of each of the nucleic acids required in
any of the above-described embodiment. Preferably the term "transformed" relates to hosts
heterologously expressing the polypeptides encoded by the nucleic acid with which they
are transformed, as well as over-expressing said polypeptides. Accordingly, in an
embodiment, the present invention provides a transformed organism, in which the
polypeptides are expressed in higher quantity than in the same organism not so
transformed.
There are several methods known in the art for the creation of transgenic host
organisms or cells such as plants, fungi, prokaryotes, or cultures of higher eukaryotic cells.
Appropriate cloning and expression vectors for use with bacterial, fungal, yeast, plant and
mammalian cellular hosts are described, for example, in Pouwels et al., Cloning Vectors: A
Laboratory Manual, 1985, Elsevier, New York and Sambrook et al., Molecular Cloning:
A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press. Cloning
and expression vectors for higher plants and/or plant cells in particular are available to the
skilled person. See for example Schardl et al. Gene 61: 1-11, 1987.

Methods for transforming host organisms or cells to harbor transgenic nucleic acids
are familiar to the skilled person. For the creation of transgenic plants, for example,
current methods include: electroporation of plant protoplasts, liposome-mediated
transformation, agrobacterium-mediated transformation, polyethylene-glycol-mediated
transformation, particle bombardement, microinjection of plant cells, and transformation
using viruses.
In one embodiment, transformed DNA is integrated into a chromosome of a non-
human host organism and/or cell such that a stable recombinant system results. Any
chromosomal integration method known in the art may be used in the practice of the
invention, including but not limited to recombinase-mediated cassette exchange (RMCE),
viral site-specific chromosomal insertion, adenovirus and pronuclear injection.
In order to carry out the method for producing α-santalene in vitro, as exposed
herein above, it is very advantageous to provide a method of making at least one
polypeptide having an α-santalene synthase activity as described in any embodiment of the
invention. Therefore, the invention provides a method for producing at least one
polypeptide according to any embodiment of the invention comprising
a) culturing a non-human host organism or cell transformed with the expression vector
of the invention, so that it harbors a nucleic acid according to the invention and
expresses or over-expresses a polypeptide of the invention;
b) isolating the polypeptide from the non-human host organism or cell cultured in step a).
According to a preferred embodiment, said method further comprises, prior to step
a), transforming a non-human host organism or cell with the expression vector of the
invention, so that it harbors a nucleic acid according to the invention and expresses or
over-expresses the polypeptide of the invention.
A nucleic acid according to any of the above-described embodiments can be used.
Transforming and culturing of the non-human host organism or cell can be carried
out as described above for the method of producing α-santalene in vivo. Step b) may be
performed using any technique well known in the art to isolate a particular polypeptide
from an organism or cell.

A "polypeptide variant" as referred to herein means a polypeptide having an α-
santalene synthase activity and being substantially homologous to the polypeptide
according to any of the above embodiments, but having an amino acid sequence different
from that encoded by any of the nucleic acid sequences of the invention because of one or
more deletions, insertions or substitutions.
Variants can comprise conservatively substituted sequences, meaning that a given
amino acid residue is replaced by a residue having similar physiochemical characteristics.
Examples of conservative substitutions include substitution of one aliphatic residue for
another, such as He, Val, Leu, or Ala for one another, or substitutions of one polar residue
for another, such as between Lys and Arg; Glu and Asp; or Gin and Asn. See Zubay,
Biochemistry, 1983, Addison-Wesley Pub. Co. The effects of such substitutions can be
calculated using substitution score matrices such a PAM-120, PAM-200, and PAM-250 as
discussed in Altschul, J. Mol. Biol., 1991, 219, 555-565. Other such conservative
substitutions, for example substitutions of entire regions having similar hydrophobicity
characteristics, are well known.
Naturally occurring peptide variants are also encompassed by the invention.
Examples of such variants are proteins that result from alternate mRNA splicing events or
from proteolytic cleavage of the polypeptides described herein. Variations attributable to
proteolysis include, for example, differences in the N- or C-termini upon expression in
different types of host cells, due to proteolytic removal of one or more terminal amino
acids from the polypeptides encoded by the sequences of the invention.
Variants of the polypeptides of the invention may be used to attain for example
desired enhanced or reduced enzymatic activity, modified regiochemistry or
stereochemistry, or altered substrate utilization or product distribution, increased affinity
for the substrate, improved specificity for the production of one or more desired
compounds, increased velocity of the enzyme reaction, higher activity or stability in a
specific environment (pH, temperature, solvent, etc), or improved expression level in a
desired expression system. A variant or site directed mutant may be made by any method
known in the art. Variants and derivatives of native polypeptides can be obtained by
isolating naturally-occurring variants, or the nucleotide sequence of variants, of other or
same plant lines or species, or by artificially programming mutations of nucleotide

sequences coding for the polypeptides of the invention. Alterations of the native amino
acid sequence can be accomplished by any of a number of conventional methods.
Polypeptide variants resulting from a fusion of additional peptide sequences at the
amino and carboxyl terminal ends of the polypeptides of the invention can be used to
enhance expression of the polypeptides, be useful in the purification of the protein or
improve the enzymatic activity of the polypeptide in a desired environment or expression
system. Such additional peptide sequences may be signal peptides, for example.
Accordingly, the present invention encompasses variants of the polypeptides of the
invention, such as those obtained by fusion with other oligo- or polypeptides and/or those
which are linked to signal peptides. Fusion polypeptide encompassed by the invention also
comprise fusion polypeptides resulting from a fusion of other functional proteins, such as
other proteins from the terpene biosynthesis pathway.
Therefore, in an embodiment, the present invention provides a method for
preparing a variant polypeptide having an α-santalene synthase activity, as described in any
of the above embodiments, and comprising the steps of:
(a) selecting a nucleic acid according to any of the embodiments exposed above;
(b) modifying the selected nucleic acid to obtain at least one mutant nucleic acid;
(c) transforming host cells or unicellular organisms with the mutant nucleic acid
sequence to express a polypeptide encoded by the mutant nucleic acid sequence;
(d) screening the polypeptide for at least one modified property; and,
(e) optionally, if the polypeptide has no desired variant α-santalene synthase activity,
repeating the process steps (a) to (d) until a polypeptide with a desired variant a-
santalene synthase activity is obtained;
(f) optionally, if a polypeptide having a desired variant α-santalene synthase activity was
identified in step d), isolating the corresponding mutant nucleic acid obtained in step
(c).
According to a preferred embodiment, the variant polypeptide prepared is capable
of producing α-santalene as a major product. According to an even more preferred
embodiment, it is capable of producing a mixture of sesquiterpenes wherein α-santalene
represents at least 60%, preferably at least 80%, preferably at least 90%, preferably at least
92% of the sesquiterpenes produced.
According to a more preferred embodiment, the variant polypeptide prepared has a

(+)-α-santalene synthase activity.
According to an even more preferred embodiment, the variant polypeptide
prepared is capable of producing (+)-α-santalene as a major product. According to an even
more preferred embodiment, it is capable of producing a mixture of sesquiterpenes wherein
(+)-α-santalene represents at least 60%, preferably at least 80%, preferably at least 90%,
preferably at least 92% of the sesquiterpenes produced.
In step (b), a large number of mutant nucleic acid sequences may be created, for
example by random mutagenesis, site-specific mutagenesis, or DNA shuffling. The detailed
procedures of gene shuffling are found in Stemmer, DNA shuffling by random
fragmentation and reassembly: in vitro recombination for molecular evolution. Proc Natl
Acad Sci U S A., 1994, 91(22): 10747-1075. In short, DNA shuffling refers to a process
of random recombination of known sequences in vitro, involving at least two nucleic acids
selected for recombination. For example mutations can be introduced at particular loci by
synthesizing oligonucleotides containing a mutant sequence, flanked by restriction sites
enabling ligation to fragments of the native sequence. Following ligation, the resulting
reconstructed sequence encodes an analog having the desired amino acid insertion,
substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis
procedures can be employed to provide an altered gene wherein predetermined codons can
be altered by substitution, deletion or insertion.
Accordingly, the polypeptide comprising SEQ ID NO:1 may be recombined with
any other sesquiterpene synthase encoding nucleic acids, for example isolated from an
organism other than Clausena lansium. Thus, mutant nucleic acids may be obtained and
separated, which may be used for transforming a host cell according to standard
procedures, for example such as disclosed in the present examples.
In step (d), the polypeptide obtained in step (c) is screened for at least one
modified property, for example a desired modified enzymatic activity. Examples of desired
enzymatic activities, for which an expressed polypeptide may be screened, include
enhanced or reduced enzymatic activity, as measured by KM or Vmax value, modified regio-
chemistry or stereochemistry and altered substrate utilization or product distribution. The
screening of enzymatic activity can be performed according to procedures familiar to the
skilled person and those disclosed in the present examples.

Step (e) provides for repetition of process steps (a)-(d), which may preferably be
performed in parallel. Accordingly, by creating a significant number of mutant nucleic
acids, many host cells may be transformed with different mutant nucleic acids at the same
time, allowing for the subsequent screening of an elevated number of polypeptides. The
chances of obtaining a desired variant polypeptide may thus be increased at the discretion
of the skilled person.
All the publications mentioned in this application are incorporated by reference to
disclose and describe the methods and/or materials in connection with which the
publications are cited.
Description of the drawings
Figure 1: Amino acid sequences deduced from the fragments of sesquiterpene
synthases obtained from the sequencing of the C. lansium library and aligned with the
amino acid sequence of sesquiterpene synthase with the NCBI access No. AAK54279.
Figure 2: Comparison of the product profiles obtained from E.E-FPP with the
Cont2-l, Cont2B_22, Cont2B_26 and Cont2B_29 recombinant proteins. The analysis
were made by GC-MS and the total ion chromatograms are shown.
Figure 3: Identification α-santalene by comparison of the mass spectrum from the
peak at retention time of 12.63 minutes and the mass spectrum of an α-santalene authentic
standard.
Specific embodiments of the invention or Examples
The invention will now be described in further detail by way of the following
Examples.

Example 1
Plant material and cDNA library construction
Seeds of Clausena lansium (wampee) were obtained from farmers located in the
Hainan province in China and particularly in the town of FuShan (ChengMai County) and
the town of Yongxing (Haikou City). The seeds were germinated and the plants cultivated
in a greenhouse.
Young leaves (1 to 2 cm long) were collected and used for the construction of a
cDNA library. Total RNA was extracted from the leaves using the Concert™ Plant RNA
Reagent from Invitrogen (Carlsbad, CA) and the mRNA were purified by oligodT-
cellulose affinity chromatography using the FastTrack® 2.0 mRNA isolation Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. A cDNA library
was constructed from this mRNA and using the Marathon™ cDNA Amplification Kit
(Clontech, Mountain View, CA).
Example 2
Massively parallel sequencing of the C. lansium leaf cDNA library
We used the technology of massive parallel sequencing of small DNA fragments
developed by Illumina (San Diego, California) to obtain sequence information of the whole
cDNA library made from wampee small leaves. This sequencing technique uses a
reversible terminator-based sequencing chemistry and the Cluster Station and Genome
Sequencer apparatuses developed by Solexa and Illumina (www.illumina.com).
The cDNA library (1 µg) was first loaded on an agarose gel and the bands
corresponding to a size between 1.5 and 3 Kb were excised, eluted and used for the
sequencing. This size enrichment avoids the dilution of the library by some cDNAs
encoding for proteins involved in primary metabolism (such as for example the ribulose-
1,5-bisphosphate carboxylase) which often are present in high proportion in library made
from plant tissues and specially green tissues. The target cDNAs, encoding for
sesquiterpene synthases, typically have a size between 1.8 and 2.5 Kb and are thus
included in the size enriched library.

The Ilumina technology and equipment was set up at Fastens SA (Geneva,
Switzerland) and the preparation of the DNA sample and the sequencing were performed
by Fastens SA. The cDNA library was treated using the Genomic Sample Prep Kit
(Illumina). Briefly, the DNA is fragmented by nebulization, the ends are repaired to
generate blunt ends, adapters are ligated to the ends of the DNA fragments and the
adapter-modified DNA fragments are amplified by PCR. After controlling the quality of
the library by gel electrophoresis, the generation of the DNA clusters on the flow cell and
the sequencing reaction is performed on the Cluster Station and Genome Sequencer
equipments. Using this technology, 1.9 millions of short sequences (reads) of at least 35
bases were obtained.
The Edena software (Dr David Hernandez, Genomic Research Laboratory,
University of Geneva Hospitals, Geneva, Switzerland, unpublished result) was used to
reassemble contiguous sequences. The five last bases were first removed from each read
because of possible miss-incorporations due to the lower fidelity in the last cycles of the
sequencing procedure. Several sets of contigs (contiguous sequences) were generated. For
each set, the contigs of minimum length of 50 bases were retained. First the software
parameters were set to allow assembly with 25 bases minimum overlap and either strict
(100%) or non-strict (2 bases miss-match) identity. Two sets of 3634 and 3756 contigs
respectively were thus generated. Another set of 4540 contigs was generated by allowing
assemble with a minimum of 18 bases and non-strict overlap. The sequences of the contigs
were used to search for homology with terpene synthases in publicly available protein
databases using the Blastx algorithm (Altschul et al, J. Mol. Biol. 215, 403-410, 1990;
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). From the three set of contigs, 14, 15 and 14
contigs were selected. Throughout the analysis of the sequences obtained from the
Clausena lansium cDNA library, strong sequence homology was observed with sequences
from citrus species, an observation consistent with the phylogenic relationship of Clausena
lansium and Citrus species (both belonging to the Rutaceae family). Thus, the Eland
software (Illumina) was used to search the non-assembled reads for DNA sequence
identity with sequiterpene synthases from citrus (NCBI Accession No. CQ813507,
CQ813505, CQ813508, CQ813506). From this analysis, 117 reads were selected.
The selected contigs and reads were then processes using the CAP program
(Huang, Genomics 14(1), 18-25, 1992) and new contigs were generated. After

confirmation of sequence homology with sesquiterpene synthases, 17 contigs of length
from 30 to 436 bases were retained (see SEQ ID NO:3 to 19). The deduced sequences
were aligned with a citrus sesquiterpene synthase (the C. junos beta-faraesene synthase,
NCBI access No. AAK54279) sequence in order to map their relative position along a full-
length sesquiterpene synthase sequence and evaluate the number of different sesquiterpene
cDNA present (Figure 1). A set of specific oligonucleotides were designed from 6 of the
19 contigs presumably arising from distinct sesquiterpene synthases cDNAs.
Example 3
Amplification of full-length sesquiterpene synthases cDNAs
The sesquiterpene synthases-specific primers deduced from the massively parallel
sequencing (Example 2) were used in combination with cDNA adaptor primers in
3 75'RACE type PCR amplifications. The amplifications were performed using the
C. lansium cDNA library, prepared as described above in Example 1, and the Advantage®
2 Polymerase Mix (Clontech) following the Marathon™ cDNA Amplification Kit protocol
(Clontech, Mountain View, CA). The thermal Cycling conditions were as follows: 1 min at
94°C, 32 cycles of 1 min at 94°C and 3 min at 68°C, and 3 min at 68°C.
Using the FS2_cont2_Fl primer (SEQ ID NO:20), a 1049 bp DNA sequence was
obtained. Analysis of the sequences of several clones obtained from this amplification
showed that two sequence variants were present (Cont2_RACE_Fl (SEQ ID NO:23) and
Cont2_RACE_F2 (SEQ ID NO:25)) with 96% sequence identity. Each of the two
sequences corresponded to the 3'end of a sesquiterpene synthase cDNA and contained a
735 bp coding region. The two deduced amino acid sequences (SEQ ID NO:24 and 26)
had 92% sequence identity to each other. With the primer FS2_cont2_Rl (SEQ ID
NO:21), a 1101 bp fragment (Cont2_RACE_R, SEQ ID NO:27)) was amplified
containing the start codon and encoding for the 349 N-terminal amino acids of the
sesquiterpene corresponding to the contig2. Alignment of the two sequences from the
3'RACE (Cont2_RACE_Fl and Cont2_RACE_F2, SEQ ID NO:23 and 25) with the
sequence from the 5'RACE (cont2_RACE_R, SEQ ID NO:27) showed an overlap of 132
bases. In this overlapping region, the Cont2_RACE_F2 and Cont2_RACE_R sequences
(SEQ ID NO:25 and 27) were nearly identical (one single base difference) whereas 9 bases

differences were observed between the Cont2_RACE_F1 and Cont2_RACE_R sequences
(SEQ ID NO:23 and 27). Thus the sequences Cont2_RACE_F2 (SEQ ID NO:25) and
Cont2_RACE_R (SEQ ID NO:27) were used to reconstitute a full-length cDNA sequence
(Cont2 RACE1, SEQ ID NO:28) encoding for a 551 amino acids protein (SEQ ID
NO:29).
With the FS2_Cont10_F primer (SEQ ID NO:22) two 1342 bp sequences
(Cont10_RACE_Fa and ContlOJRACEFb, SEQ ID NO: 30 and 31) were obtained
showing significant differences (67 bp, representing 95% DNA sequence identity) and
suggesting the presence of two closely related sesquiterpene synthase cDNAs. The two
sequences contained a 1135 bp coding region. Interestingly the sequence of
Cont10_RACEFa (SEQ ID NO:30) was 99.9% identical to the sequence of
Cont2_RACE_F2 (SEQ ID NO:25, only 1 bases difference on the 1 Kb alignment) and the
sequence of Cont10_RACE_Fb (SEQ ID NO:31) was 99% identical to the sequence of
Cont2_RACE_F1 (SEQ ID NO:23, only 8 bases difference on the 1 Kb alignment), thus
suggesting that the DNA fragments amplified with the Cont2 and Cont10 primers allowed
amplifications from two related sequences with no real discrimination. Two primers
(Cont2_start (SEQ ID NO:32) and Cont2_stop (SEQ ID NO:33)), which are specific to
the regions of the start and the stop codons of the sequences from the 5'RACE and the
3'RACE of the cont2 and cont10 fragments, were designed in order to amplify
simultaneously the two or more corresponding full-length cDNAs. The primer Cont2_start
(SEQ ID NO:32) was extended with the CACC sequence to allow direct insertion into the
pET101/D-TOPO plasmid (Invitrogen). The amplification was first performed using the
Advantage® 2 Polymerase Mix (Clontech). Each PCR mixture contained, in a total volume
of 50 µL, 5µL of Advantage® 2 PCR Buffer, 200 µM dNTPs, 200 nM each
oligonucleotide primer, 5 µL of 100 fold diluted cDNA and 1 µL of Advantage® 2
Polymerase Mix. The thermal cycling conditions were as follows: 2 min at 95°C; 35 cycles
of 30 sec at 95°C, 30 sec at 60°C and 4 min at 72°C; and 10 min at 72°C. A second round
of amplification was then performed using 5 µl of the purified PCR product from the first
round of amplification and using the Pfu DNA polymerase (Promega), in a final volume of
50 µl containing 5µl of Pfu DNA polymerase 10X buffer, 200 µM each dNTP, 0.4 µM
each forward and reverse primer, 2.9 units Pfu DNA polymerase. The thermal cycling

conditions were identical to the conditions used in the first round. The purified PCR
products were ligated in the pET1001/D-TOPO vector following the manufacturer's
instructions (Invitrogen). Several clones were selected and after sequencing of the insert,
some variations in the sequences were observed. The following clones were selected:
Cont2-l (SEQ ID NO:2), Cont2B_22 (SEQ ID NO:38), Cont2B_26 (SEQ ID NO:39)
and Cont2B_29 (SEQ ID NO:40). The sequences of the proteins encoded by these clones
are provided in SEQ ID NO:1 and 41 to 43, respectively.
Example 4
Heterologous expression and enzymatic activities of the recombinant sesquiterpene
synthases.
The plasmids pET101 with Cont2_1 (SEQ ID NO:2), Cont2B_22 (SEQ ID
NO:38), Cont2B_26 (SEQ ID NO:39) and Cont2B_29 (SEQ ID NO:40) prepared as
described in Example 3 were transformed into B121(DE3) E. Coli cells. Single colonies of
transformed cells were used to inoculate 5 ml LB medium. After 5 to 6 hours incubation at
37°C, the culture was transferred to a 20°C incubator and left 1 hour for equilibration.
Expression of the protein was then induced by the addition of 1 mM IPTG and the culture
was incubated over-night at 20°C. The next day, the cells were collected by centrifugation,
re-suspended in 0.1 volume of 50 mM MOPSO pH 7, 10% glycerol, 1 mM DTT and lysed
by sonication. The extract was cleared by centrifugation (30 min at 20,000 g), and the
supernatant containing the soluble protein was used for further experiments.
The crude protein extract was used to evaluate the enzymatic activity. The
enzymatic assay was performed in a Teflon sealed glass tube using 50 to 100 µl of protein
extract in a final volume of 1 mL of 50 mM MOPSO pH 7, 10% glycerol supplemented
with 1 mM DTT, 20 mM MgCl2 and 50 to 200 µM purified E,E-farnesyl diphosphate
(FPP) (prepared as described by Keller and Thompson, J. Chromatogr 645(1), 161-167,
1993). The tube was incubated 18 to 24 hours at 30°C and the enzyme products were
extracted twice with one volume of pentane. After concentration under a nitrogen flux, the
extract was analyzed by GC and the identity of the products was confirmed by GC-MS
based on the concordance of the retention indices and mass spectra of authentic standards.
The GC-MS analysis was performed on a Hewlett-Packard 6890 Series GC system

equipped with a flame ionization detector using a 0.25 mm inner diameter by 30 m SPB-1
capillary column (Supelco, Bellefonte, PA). The carrier gas was He at a constant flow of
1.5 mL/min. The initial oven temperature was 80°C followed by a gradient of 10°C/min to
280°C. The spectra were recorded at 70eV with an electron multiplier voltage of 2200V.
The assay revealed the formation of (+)-α-santalene as a major product (92.7% of
the total sesquiterpenes produced) and traces amounts of five additional sesquiterpenes
accounting for 4.8 to 0.95% of the enzyme products. (+)-α-santalene was identified with
GC-MS analysis by coincidence of the mass spectrum and of the retention index with
published values (Joulain, D., and Konig, W.A. The Atlas of Spectral Data of
Sesquiterpene Hydrocarbons, EB Verlag, Hamburg, 1998). The The identification of (+)-
α-santalene was further confirmed by 1H NMR, 13C NMR and by measurement of the
optical rotation. To produce sufficient quantities for these measurements, the enzymatic
assay described above was scaled up to 1 L. The enzyme products were extracted with an
equal volume of pentane, concentrated and the sesquiterpene hydrocarbons fraction
(5.5 mg) purified by filtration on a short silica column, spectral data obtained with
Cont2_l is provided in Figure 2.
The NMR spectrum was recorded on a Bruker-Avance-500 spectrometer. The
NMR data is the following :
1H NMR (500.13 MHz, CDCl3): δ 0.82 (s, 2H), 0.83 (s, 3H), 0.99 (s, 3H), 1.00-1.08 (m,
2H), 1.08-1.26 (m, 2H), 1.57-1.63 (m, 6H), 1.68 (s, 3H), 5.12 (t × q,J= 7.2, 1.4 Hz, 1H)
I3C NMR (125.76 MHz, CDCl3): δ 10.7 (q), 17.5 (q), 19.6 (d), 23.3 (t), 25.7 (q), 27.4 (s),
31.0 (t), 31.5 (t), 34.6 (t), 38.2 (d), 45.9 (s), 125.5 (d), 130.8 (s);
The fact that the (+)-α-santalene stereoisomer was produced has been evidenced by
measuring the optical rotation (as measured on a Perkin-elmer 241 polarimeter):
[α]20D = +12.0 (C = 0.3, CHCl3).

Example 5
In-vivo production of (+)-α-santalene in E coli
The use of the C. lansium santalene synthase for the in-vivo production of
sesquiterpenes in E coli cells was evaluated by co-expressing the sesquiterpene synthase
with a FPP synthase and the enzymes of a four step biosynthetic pathway allowing the
conversion of mevalonate to FPP. The mevalonate pathway genes were organized in a
single operon and encoded for a mevalonate kinase (mvaK1), a phosphomevalonate kinase
(mvaK2), a mevalonate diphosphate decarboxylase (MvaD) and an isopentenyl
diphosphate isomerase (idi), all the enzymes converting exogenous mevalonate to
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), the two substrates
of the FPP synthase. The co-expression of this partial mevalonate pathway was used to
increase the amount of intracellular FPP available for the sesquiterpene synthase and thus
the quantities of sesquiterpene produced.
The yeast FPP synthase gene (Accession number J05091) was amplified from
S. cerevisiae genomic DNA using the primers FPPy_Ncol (SEQ ID NO:34) and FPPy-
Eco (SEQ ID NO:35). The genomic DNA was isolated from S. cerevisiae using the
Qiagen RNA/DNA Maxi Kit (Qiagen AG, Basel, Switzerland). The PCR was performed
with the Pfu DNA polymerase (Promega AG, Dubendorf, Switzerland) in a final volume of
50 µl containing 0.4 ul of each primer, 200 µM dNTPs, 0.5 µl DNA polymerase 5 µl
S. cerevisiae genomic DNA. The PCR cycling condition were as follows: 90 sec at 95°C;
28 cycles of 45 sec at 95°C, 30 sec at 54°C and 4 min at 72°C; 10 min at 72°C. The
amplified DNA was ligated as Ndel-EcoRI fragment in the first multi cloning site (MCS1)
of the pACYCDuet-1 plasmid (Novagen, Madison, WI) providing the plasmid
pACYCDuet-FPPs harbouring the FPPs gene under the control of a T7 promoter.
An operon containing the genes encoding for mvaK1, mvaK2, MvaD and idi was
amplified from genomic DNA of Streptococcus pneumoniae (ATCC BAA-334, LGC
Standards, Molsheim, France) with the primers MVA-up1-start (SEQ ID NO:36) and
MVA-up2-stop (SEQ ID NO:37). The PCR was performed using the PfuUltra™ II Fusion
HS DNA polymerase (Stratagene, Agilent Technologies Inc., Santa Clara, CA, USA). The
composition of the PCR mix was according to the manufacturer's instructions. The
thermal cycling conditions were 2 min at 95°C; 30 cycles of 20 sec at 95°C, 20 sec at 58°C

and 90 sec at 72°C; and 3 min at 72°C. The 3.8 Kb fragment was purified on an agarose
gel and ligated using the In-Fusion™ Dry-Down PCR Cloning Kit (Clontech Laboratories)
into the second MCS of the pACYCDuet-FPPs plasmid digested with NdeI and XhoI
providing the plasmid pACYCDuet-4506. The sequences of the two inserts were fully
sequenced to exclude any mutation.
BL21 Star™(DE3) E. coli cells (Invitrogen, Carlsbad, CA) were transformed with
the plasmids pET101-cont2_1 (SEQ ID NO:2) prepared as described in Example 3 and
with the plasmid pACYCDuet-4506. Transformed cells were selected on carbenicillin
(50 µg/ml) and chloramphenicol (34 µg/ml) LB-agarose plates. Single colonies were used
to inoculate 5 mL liquid LB medium supplemented with the same antibiotics. The culture
was incubated overnight at 37°C. The next day 2 mL of TB medium supplemented with
the same antibiotics were inoculated with 0.2 mL of the overnight culture. After 6 hours
incubation at 37°C, the culture was cooled down to 28°C and 1 mM IPTG, 2 mg/mL
mevalonate (prepared by dissolving mevalonolactone (Sigma) in 0.5N NaOH at a
concentration of 1 g/mL and incubating the solution for 30 min at 37°C) and 0.2 ml decane
were added to each tube. The cultures were incubated for 48 hours at 28°C. The cultures
were then extracted twice with 2 volumes of ethyl-acetate, the organic phase was
concentrated to 500 uL and analyzed by GC-MS as described above in Example 4. In
these conditions the cells produced (+)-α-santalene at 250 mg/L culture in 48 hours.
This example shows that an E. coli cell transformed with an α-santalene synthase,
as defined in the present invention, is capable of producing α-santalene. The other enzymes
with which the E. coli cell is transformed are not essential for the production of a-
santalene. Indeed α-santalene is also produced when an E. coli cell is transformed with the
α-santalene synthase only, but in lower amounts. The other enzymes with which the E. coli
cell is transformed are added for the only purpose of increasing the amount of precursor
available to the α-santalene synthase.

Claims
1. A method for producing α-santalene comprising
a) contacting FPP with at least one polypeptide having an α-santalene synthase activity
and comprising an amino acid sequence at least 50% identical to SEQ ID NO:1;
b) optionally, isolating the α-santalene produced in step a).

2. The method of claim 1, wherein step a) comprises cultivating a non-human
host organism or cell capable of producing FPP and transformed to express at least one
polypeptide comprising an amino acid sequence at least 50% identical to SEQ ID NO:1
and having an α-santalene synthase activity, under conditions conducive to the production
of α-santalene.
3. The method of claim 2, wherein the method further comprises, prior to step
a), transforming a non human host organism or cell capable of producing FPP with at least
one nucleic acid encoding a polypeptide comprising an amino acid sequence at least 50%
identical to SEQ ID NO:1 and having an α-santalene synthase activity, so that said
organism expresses said polypeptide.
4. The method of claim 3, wherein the at least one nucleic acid encoding the
α-santalene synthase comprises a nucleotide sequence at least 50%, preferably at least
70%, preferably at least 90% identical to SEQ ID NO:2 or the complement thereof.
5. The method of claim 4, wherein the nucleic acid comprises the nucleotide
sequence SEQ ID NO:2 or the complement thereof.
6. The method of claim 5, wherein the nucleic acid consists of SEQ ID NO:2
or the complement thereof.
7. The method of claim 3 or 4, wherein the at least one nucleic acid used in
any of the above embodiments comprises a nucleotide sequence that has been obtained by
modifying SEQ ID NO:2 or the complement thereof.

8. The method of any of claims 2 to 7, wherein the non-human host organism
is a plant, a prokaryote or a fungus.
9. The method of any of claims 2 to 7, wherein the non-human host organism
is a microorganism, preferably a bacteria or a yeast
10. The method of claim 9, wherein said bacteria is E. coli and said yeast is
Saccharomyces cerevisiae
11. The method of any of claims 2 to 7, wherein said non-human host cell is a
plant or a fungal cell.
12. The method of any of the preceding claims, for producing α-santalene as a
major product.
13. The method of claim 12, wherein α-santalene represents at least 60%,
preferably at least 80%, preferably at least 90%, of the sesquiterpenes obtained.
14. The method according to any of the preceding claims, for producing (+)-α-
santalene and wherein the polypeptide having an α-santalene synthase activity has a (+)-α-
santalene synthase activity.
15. The method of claim 14, wherein (+)-α-santalene is obtained as a major
product.
16. The method of claim 15, wherein (+)-α-santalene represents at least 60%,
preferably at least 80%, preferably at least 90% of the sesquiterpenes obtained.
17. The method of any of the preceding claims, wherein the at least one
polypeptide comprises an amino acid sequence at least 70%, preferably at least 90%
identical to SEQ ID NO:1.

18. The method of claim 17, wherein the at least one polypeptide comprises the
amino acid sequence SEQ ID NO:1.
19. The method of claim 18, wherein the at least one polypeptide consists of
SEQ ID NO: 1
20. The method of any of claims 1 to 4 or 7 to 17, wherein the at least one
polypeptide comprises an amino acid sequence that has been obtained by modifying SEQ
IDNO:1.
21. A polypeptide having an α-santalene synthase activity and comprising an
amino acid sequence at least 50% identical to SEQ ID NO:1.
22. The polypeptide of claim 21, wherein said polypeptide is capable of
producing α-santalene as a major product.
23. The polypeptide of claim 22, wherein said polypeptide is capable of
producing a mixture of sesquiterpenes wherein α-santalene represents at least 60%,
preferably at least 80%, preferably at least 90% of the sesquiterpenes produced.
24. The polypeptide of claim 21, wherein said polypeptide has a (+)-α-santalene
synthase activity.
25. The polypeptide of claim 24, wherein said polypeptide is capable of
producing (+)-α-santalene as a major product.
26. The polypeptide of claim 25, wherein said polypeptide is capable of
producing a mixture of sesquiterpenes wherein (+)-α-santalene represents at least 60%,
preferably at least 80%, preferably at least 90% of the sesquiterpenes produced.

27. The polypeptide of any of claims 21 to 26, wherein said polypeptide
comprises an amino acid sequence at least 70%, preferably at least 90% identical to SEQ
ID NO:1.
28. The polypeptide of claim 27, wherein said polypeptide comprises the amino
acid sequence SEQ ID NO:1.
29. The polypeptide of claim 28, wherein said polypeptide consists of SEQ ID
NO:1.
30. The polypeptide of any of claims 21 to 27, wherein said polypeptide
comprises an amino acid sequence that has been obtained by modifying SEQ ID NO: 1.
31. A nucleic acid encoding a polypeptide according to any of claims 21 to 30.
32. The nucleic acid of claim 31, comprising a nucleotide sequence at least
50%, preferably at least 70%, preferably at least 90% identical to SEQ ID NO:2 or the
complement thereof.
33. The nucleic acid of claim 32, comprising the nucleotide sequence SEQ ID
NO:2 or the complement thereof.
34. The nucleic acid of claim 33, consisting of SEQ ID NO:2 or the
complement thereof.
35. The nucleic acid of claim 31 or 32, comprising a nucleotide sequence that
has been obtained by modifying SEQ ID NO:2 or the complement thereof.
36. An expression vector comprising the nucleic acid of any of claims 31 to 35.
37. The expression vector of claim 36, in the form of a viral vector, a
bacteriophage or a plasmid.

38. The expression vector of claim 36 or 37, including the nucleic acid of the
invention operably linked to at least one regulatory sequence which controls transcription,
translation initiation or termination, such as a transcriptional promoter, operator or
enhancer or an mRNA ribosomal binding site and, optionally, including at least one
selection marker.
39. A non-human host organism or cell transformed to harbor at least one
nucleic acid according to any of claims 31 to 35, so that it heterologously expresses or
over-expresses at least one polypeptide according to any of claims 21 to 30.
40. The non-human host organism of claim 39, wherein said non-human host
organism is a plant, a prokaryote or a fungus.
41. The non-human host organism of claim 39, wherein said non-human host
organism is a microorganism, preferably a bacteria or yeast.
42. The non-human host organism of claim 41, wherein said bacteria is E. coli
and said yeast is Saccharomyces cerevisiae.
43. The higher eukaryotic cell of claim 39, wherein said higher eukaryotic cell
is a plant cell or a fungal cell.
44. A method for producing at least one polypeptide according to any of claims
21 to 30 comprising

a) culturing a non-human host organism or cell transformed with the expression vector
of any of claims 36 to 38, so that it harbors a nucleic acid according to any of claims
31 to 35 and expresses or over-expresses a polypeptide according to any of claims 21
to 30;
b) isolating the polypeptide from the non-human host organism or cell cultured in step a).

45. The method of claim 44, further comprising, prior to step a), transforming a
non-human host organism or cell with the expression vector of any of claim 36 to 38, so
that it harbors a nucleic acid according to any of claims 31 to 35 and expresses or over-
expresses the polypeptide of any of claims 21 to30.
46. A method for preparing a variant polypeptide having an α-santalene
synthase activity comprising the steps of:

(a) selecting a nucleic acid according to any of the claims 31 to 35;
(b) modifying the selected nucleic acid to obtain at least one mutant nucleic acid;
(c) transforming host cells or unicellular organisms with the mutant nucleic acid
sequence to express a polypeptide encoded by the mutant nucleic acid sequence;
(d) screening the polypeptide for at least one modified property; and,
(e) optionally, if the polypeptide has no desired variant α-santalene synthase activity,
repeating the process steps (a) to (d) until a polypeptide with a desired variant a-
santalene synthase activity is obtained;
(f) optionally, if a polypeptide having a desired variant α-santalene synthase activity was
identified in step d), isolating the corresponding mutant nucleic acid obtained in step
(c).

47. A method according to claim 46, wherein the variant polypeptide prepared
is capable of producing α-santalene as a major product.
48. A method according to claim 47, wherein the variant polypeptide prepared
is capable of producing a mixture of sesquiterpenes wherein α-santalene represents at least
60%, preferably at least 80%, preferably at least 90% of the sesquiterpenes produced.
49. A method according to claim 46, wherein the variant polypeptide prepared
has a (+)-α-santalene synthase activity.
50. A method according to claim 49, wherein the variant polypeptide prepared
is capable of producing (+)-α-santalene as a major product.

51. A method according to claim 50, wherein the variant polypeptide prepared
is capable of producing a mixture of sesquiterpenes wherein (+)-α-santalene represents at
least 60%, preferably at least 80%, preferably at least 90% of the sesquiterpenes produced.

The present invention provides a method of producing α-santalene, said method comprising contacting at least one
polypeptide with farnesyl phyrophosphate (FPP). In particular, said method may be carried out in vitro or in vivo to produce α-santalene,
a very useful compound in the fields of perfumery and flavoring. The present invention also provides the amino acid sequence
of a polypeptide useful in the method of the invention. A nucleic acid encoding the polypeptide of the invention and an expression
vector containing said nucleic acid are also part of the present invention. A non-human host organism or a cell transformed
to be used in the method of producing α-santalene is also an object of the present invention.